May/June 2011, Vol 4, No 3

Business

Utilization, Spending, and Price Trends for Short- and Long-Acting Beta-Agonists and Inhaled Corticosteroids in the Medicaid Program, 1991-2010
Shih-Feng Chiu, MPH
; Christina M. L. Kelton, PhD
; Jeff Jianfei Guo, MS, BPharm, PhD
; Patricia R. Wigle, PharmD
; Alex C. Lin, PhD
; Sheryl L. Szeinbach, PhD, RPh
Stakeholder Perspective by Bryan Amick, PharmD, MBA
The Economic Impact of Delaying 5-Alpha Reductase Inhibitor Therapy in Men Receiving Treatment for Symptomatic Benign Prostatic Hyperplasia
Michael Naslund, MD, MBA
; Michael T. Eaddy, PharmD, PhD
; Susan L. Hogue, PharmD, MPH
; Eric J. Kruep, PharmD, MS
; Manan B. Shah, PharmD, PhD
Stakeholder Perspective by Matthew Mitchell, PharmD, MBA

Clinical

From A to Z: Medication Cost-Management Strategies for Disproportionate Share Hospitals
Andrea Henry, PharmD, MBA
; Goldina Ikezuagu Erowele, PharmD
; Uche Anadu Ndefo, PharmD, BCPS
; Jackie Milton-Brown, PharmD
; Enock Anassi, PharmD, MD
; Wendy Green, PharmD, MPA
; Adriana Alvidrez, PharmD, BCPS
; Alphonsus U. Okpara, PharmD
Stakeholder Perspective by Diana Rangaves, PharmD

Perspective

Systematic Health Management: The Time Has Come to Do the Right Thing for Each Person
Jeff Rideout, MD, MA, FACP

AMCP HIGHLIGHTS

Economic and Clinical Value of Integrating a Clinical Pharmacist into the Care Management Team
Impact of Value-Based Insurance Design on Medication Utilization and Costs in a Large Retail Employer
Current Trends in the Pharmaceutical Pipeline: Key Players to Watch, Few Surprises
Degree of Adherence in Chronic Diseases Inversely Correlates with Healthcare Costs
Do Medication Therapy Management Programs Achieve Their Goals?